4 Jefferies Top Value Stock Picks to Buy Now
A new research report from Jefferies highlights value stocks to buy this week. These four stocks have the biggest upside to the posted price targets.
A new research report from Jefferies highlights value stocks to buy this week. These four stocks have the biggest upside to the posted price targets.
A new research report from UBS makes an interesting tech switch in the Dividend Rulers portfolio. We also update the other two large cap tech stocks that remain in the Dividend Rulers list.
The stock market remains a place to invest even though interest rates are poised to rise. Finding good growth stocks that have not been momentum darlings has been a challenge.
Merrill Lynch has looked at large cap biotech leaders and how interest rate increases may play a part in stock performance.
One thing is for sure, as the earnings season concludes, our suspicion that windows of opportunity would open for insiders is proving to be spot on.
All corporations stop insider transactions around the reporting date to avoid the look of any impropriety, and they appear to be resuming with a vengeance.
24/7 Wall St. screened the Merrill Lynch utility stock universe and found four outstanding large-cap utility stocks that are rated Buy at the firm and make good sense for investors now.
A new report from Jefferies have found three top MLPs that may be outstanding buys for investors as they do not need to raise capital and could be somewhat insulated from further downward selling…
Oppenheimer's portfolio strategy team has combed through the universe of stocks they cover and found a group that falls into the favorable category when it comes to the firm's quantitative screens.
One thing people tend to forget, except for certain activist investors maybe, is that Apple has a gigantic amount of cash, the majority of which is stored outside of the United States.
Now is the time to really review portfolios and replace momentum winners with earnings growth leaders. The Cowen Focus Call stocks are just the ticket.
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.
24/7 Wall St. screened the Merrill Lynch list of Buy-rated stocks with a 90-day price and volume breakout for those that make sense now as the market seems to be hitting a wall.
The research team at Jefferies is focused each week on finding good value stock calls, and it makes sense for investors in an increasing risky and expensive market to rotate to solid value ideas.
A new research report from JPMorgan stresses that the energy downturn could last the rest of 2015 and well into 2016. The question is could now be the time to be buying?
These industrial stocks are perfect for long-term growth portfolios. They pay solid dividends, are growing their businesses and are returning capital to shareholders.
In a new report, UBS made changes in the firm's Equity Focus list and updated other positions.
In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech companies could be targeted for buyouts.
SunTrust Robinson Humphrey handicaps some of the upcoming events for stocks in the firm's coverage universe that have potential market-moving clinical and FDA catalysts during the remainder of 2015.
A new comprehensive research report from Merrill Lynch takes a hard look at stocks that can benefit as energy investors wait for an increase in spot prices.